Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 161 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Hepatitis C Virus Genotype 1 Clear all
Terminated Phase 2 Interventional Results available

Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy

NCT02194998
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV

NCT00863239
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
ribavirin, Locteron™ (controlled-release interferon alpha 2b), PEG-Intron™
Drug
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Chula Vista, California • Oceanside, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures

NCT01185028
View directory record Official record
Conditions
Hepatitis C Infection, HIV Infection
Interventions
Nitazoxanide With Pegylated Interferon And Ribavirin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 3 Interventional

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

NCT01973049
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Asunaprevir, BMS-791325, Ribavirin, Placebo matching Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus

NCT01628692
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Daclatasvir, Simeprevir, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
San Francisco, California • Indianapolis, Indiana • Lutherville, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

NCT01851330
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
52
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease

NCT03036839
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Boston, Massachusetts • Detroit, Michigan • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

NCT02716428
View directory record Official record
Conditions
Hepatitis C Viral Infection, Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1
Interventions
Faldaprevir, TD-6450, Ribavirin
Drug
Lead sponsor
Trek Therapeutics, PBC
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Coronado, California • Bradenton, Florida • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

NCT01728324
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment, Ribavirin-placebo: 8-week treatment, Faldaprevir-placebo: 8-week treatment, Faldaprevir: 16-week treatment, Ribavirin: 16-week treatment, RBV: 24-week treatment, BI 207127: 16-week treatment
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
31
States / cities
North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT01306617
View directory record Official record
Conditions
Chronic Hepatitis C Infection, Hepatitis C, Hepatitis C Virus
Interventions
ABT-450, ABT-333, ribavirin, ritonavir
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

Ph IIA Study (SOC +/- NS5B)

NCT01193361
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
BMS-791325, Placebo, Peg-interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Anaheim, California • Maywood, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection

NCT01909804
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Long Beach, California • Los Angeles, California • Pasadena, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Not applicable Interventional

Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects

NCT00926016
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Pioglitazone (Actos)
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects

NCT00663208
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Daclatasvir, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Anaheim, California • Cypress, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging of GSK2336805 in Combination Therapy

NCT01648140
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a, Ribavirin, Telaprevir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
18
States / cities
Dothan, Alabama • Anaheim, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 1Phase 2 Interventional

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

NCT00664625
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-791325, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Anaheim, California • Cypress, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

NCT01241760
View directory record Official record
Conditions
Genotype 1 Chronic Hepatitis C, Treatment Naive
Interventions
Ribavirin, Telaprevir, Pegylated interferon alfa-2a
Drug
Lead sponsor
Janssen Infectious Diseases BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

NCT01399619
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
PegIFN/RBV, BI201335, BI201335 24W, Bi 201335
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
22
States / cities
Birmingham, Alabama • Palm Springs, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 1 Interventional

Study of VX-985 in Subjects With Chronic Hepatitis C

NCT01144936
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
VX-985 or matching placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Overland Park, Kansas • Baltimore, Maryland • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 9, 2011 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

NCT02378961
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
31
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 1, 2026, 10:36 PM EDT
Withdrawn Phase 2 Interventional

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I

NCT01142700
View directory record Official record
Conditions
Chronic Hepatitis C Virus Genotype 1
Interventions
BMS-824393, Placebo, Peginterferon Alpha-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Coronado, California • San Diego, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2011 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

NCT01318694
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Beverly Hills, California • Oakland, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

NCT03089944
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT01314261
View directory record Official record
Conditions
Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection
Interventions
ABT-267, Pegylated interferon (pegIFN), Ribavirin (RBV), Placebo for ABT-267
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 1, 2026, 10:36 PM EDT